Amphastar Pharmaceuticals (AMPH) Current Deferred Revenue (2013 - 2016)

Amphastar Pharmaceuticals' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $830000.0 for Q3 2016.

• In Q3 2016, Current Deferred Revenue rose 29.08% year-over-year to $830000.0; the TTM figure through Sep 2016 stood at $830000.0 (up 29.08% YoY), while the FY2015 annual figure was $643000.0, down 95.41% from the prior year.
• Current Deferred Revenue was $830000.0 for Q3 2016 at Amphastar Pharmaceuticals, down from $1.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $14.6 million in Q3 2014 to a low of $643000.0 in Q4 2013.
• Historically, Current Deferred Revenue has averaged $4.1 million across 4 years, with a median of $830000.0 in 2016.
• The sharpest annual moves came in 2014 and 2015: Current Deferred Revenue surged 2079.32% in 2014, then plunged 95.59% in 2015.
• A 4-year view of Current Deferred Revenue shows it stood at $643000.0 in 2013, then soared by 2079.32% to $14.0 million in 2014, then plunged by 95.41% to $643000.0 in 2015, then increased by 29.08% to $830000.0 in 2016.
• The last three Current Deferred Revenue figures came in at $830000.0 (Q3 2016), $1.7 million (Q2 2016), and $643000.0 (Q1 2016), per Business Quant data.